2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) All Versions of this Article: ASN.2007020166v1 18/6/1899    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jha, V. Articles by Sakhuja, V. Search for Related Content PubMed PubMed Citation Articles by Jha, V. Articles by Sakhuja, V.

A Randomized, Controlled Trial of Steroids and Cyclophosphamide in Adults with Nephrotic Syndrome Caused by Idiopathic Membranous Nephropathy

Vivekanand Jha^*, Anirban Ganguli^*, Tarun K. Saha^*, Harbir S. Kohli^*, Kamal Sud^*, Krishan L. Gupta^*, Kusum Joshi and Vinay Sakhuja^*

^* Departments of Nephrology and Histopathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India

Address correspondence to: Dr. Vivekanand Jha, Department of Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh 160 012 India. Phone: +72-275-6733; Fax: +72-274-0044; E-mail: vjha{at}pginephro.org

Received for publication February 7, 2007. Accepted for publication March 29, 2007.

Idiopathic membranous nephropathy (IMN) is the most common cause of nephrotic syndrome in adults. Universal consensus regarding the need for and the modality of therapy has not been formed because of a lack of controlled trials of sufficient size, quality, and duration. This study compared the effect of a 6-mo course of alternating prednisolone and cyclophosphamide with supportive treatment in adults with nephrotic syndrome caused by IMN on doubling of serum creatinine, development of ESRD, and quality of life in a randomized, controlled trial. Patients were followed up for 10 yr. Data were analyzed on an intention-to-treat basis. A total of 93 patients completed the study. Of the 47 patients who received the experimental protocol, 34 achieved remission (15 complete and 19 partial), compared with 16 (five complete, 11 partial) of 46 in the control group (P < 0.0001). The 10-yr dialysis-free survival was 89 and 65% (P = 0.016), and the likelihood of survival without death, dialysis, and doubling of serum creatinine were 79 and 44% (P = 0.0006) in the two groups. Treated patients exhibited significantly lower prevalence of edema, hypertension, hypoalbuminemia, hyperlipidemia that required therapy, angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker use, and better quality of life on follow-up. The incidence of infections was similar in the two groups. In conclusion, untreated IMN with nephrotic syndrome is associated with a high risk for deterioration of renal function. A 6-mo regimen of cyclophosphamide and steroids induces remissions in a high proportion, arrests progression of renal insufficiency, and improves quality of life.

This article has been cited by other articles:

				J. M. Hofstra and J. F. M. Wetzels Introduction of a cyclophosphamide-based treatment strategy and the risk of ESRD in patients with idiopathic membranous nephropathy: A nationwide survey in the Netherlands Nephrol. Dial. Transplant., November 1, 2008; 23(11): 3534 - 3538. [Abstract] [Full Text] [PDF]

				L. Senthil Nayagam, A. Ganguli, M. Rathi, H. S. Kohli, K. L. Gupta, K. Joshi, V. Sakhuja, and V. Jha Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study Nephrol. Dial. Transplant., June 1, 2008; 23(6): 1926 - 1930. [Abstract] [Full Text] [PDF]

				F. C. Fervenza, S. Sethi, and U. Specks Idiopathic Membranous Nephropathy: Diagnosis and Treatment Clin. J. Am. Soc. Nephrol., May 1, 2008; 3(3): 905 - 919. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673